MIR2053: MIR2053 is a gene that has been investigated in relation to its potential role in modulating the therapeutic response of standard treatment for acute lymphoblastic leukemia (ALL) [PMC10003057]. In a study, only one single nucleotide polymorphism (SNP) in MIR2053, specifically rs10505168, showed a significant association with GC (p = 0.008) [PMC6687864]. Additionally, this SNP was found to be associated with an increased risk of developing neurological toxicity during the treatment of ALL. The homozygous mutant TT genotype of rs10505168 was specifically linked to a fourfold increased risk of neurological toxicity compared to other genotypes (p = 0.025, OR = 4.61) [PMC10003057]. Furthermore, other genetic variants in MIR149, MIR605, and SVIL were also found to be statistically relevant and associated with neurological toxicity during ALL treatment [PMC10003057]. Overall, the study demonstrated that variants in MIR149, MIR605, SVIL, and MIR2053 could potentially influence the development of neurological toxicities during ALL treatment [PMC10003057]. These findings highlight the importance of genetic factors such as rs10505168 in MIR2053 as potential predictors for therapeutic response and adverse effects in ALL patients undergoing standard treatment [PMC10003057].